Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 210
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Oncogene ; 30(47): 4697-706, 2011 Nov 24.
Artigo em Inglês | MEDLINE | ID: mdl-21602888

RESUMO

A human endogenous retrovirus type E (HERV-E) was recently found to be selectively expressed in most renal cell carcinomas (RCCs). Importantly, antigens derived from this provirus are immunogenic, stimulating cytotoxic T cells that kill RCC cells in vitro and in vivo. Here, we show HERV-E expression is restricted to the clear cell subtype of RCC (ccRCC) characterized by an inactivation of the von Hippel-Lindau (VHL) tumor-suppressor gene with subsequent stabilization of hypoxia-inducible transcription factors (HIFs)-1α and -2α. HERV-E expression in ccRCC linearly correlated with HIF-2α levels and could be silenced in tumor cells by either transfection of normal VHL or small interfering RNA inhibition of HIF-2α. Using chromatin immunoprecipitation, we demonstrated that HIF-2α can serve as transcriptional factor for HERV-E by binding with HIF response element (HRE) localized in the proviral 5' long terminal repeat (LTR). Remarkably, the LTR was found to be hypomethylated only in HERV-E-expressing ccRCC while other tumors and normal tissues possessed a hypermethylated LTR preventing proviral expression. Taken altogether, these findings provide the first evidence that inactivation of a tumor suppressor gene can result in aberrant proviral expression in a human tumor and give insights needed for translational research aimed at boosting human immunity against antigenic components of this HERV-E.


Assuntos
Carcinoma de Células Renais/virologia , Retrovirus Endógenos/genética , Neoplasias Renais/virologia , Provírus/genética , Proteína Supressora de Tumor Von Hippel-Lindau/fisiologia , Regiões 5' não Traduzidas , Fatores de Transcrição Hélice-Alça-Hélice Básicos/fisiologia , Linhagem Celular Tumoral , Metilação de DNA , Humanos , Neoplasias Renais/etiologia , Regiões Promotoras Genéticas , Sequências Repetidas Terminais , Proteína Supressora de Tumor Von Hippel-Lindau/genética
2.
Exp Oncol ; 33(1): 33-41, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21423093

RESUMO

BACKGROUND: Human chromosome arm 3p is often affected in various epithelial tumors, and several tumor suppressor genes were recently identified in this region. The most affected is 3p21 region that is 50-100% rearranged in more than 30 types of malignancies, mostly in epithelial cancers: lung, breast, ovarian, cervical, kidney, head and neck, nasopharyngeal, colon etc. These cancers are responsible for 90% of cancer deaths. AIM: To perform the detailed analysis of 3p (especially 3p21 region) to discover novel potential oncogenes and/or tumor suppressors. METHODS: To find novel "hot spots" and genes involved in major cancers, dense 3p microsatellite markers (altogether 24 ) were allelotyped in four epithelial carcinomas (272 patients in total): breast (BC), renal cell (RCC), non-small cell lung (NSCLC) and epithelial ovarian (EOC) cancers. RESULTS: As a main result, a novel region, frequently affected in BC, RCC, NSCLC and EOC was localized between markers D3S2409 and D3S3667 in the 3p21.3. This region (MECA3, major epithelial cancers affected region No. 3) covers numerous UniGene clusters, including genes involved in vital cell functions and carcinogenesis (e.g. MST1, MSTR1/RON, GPX1 and RHOA). The homozygous deletions were detected in the GPX1 in RCC (12%, 6 of 50 cases) and BC (1 of 37 cases). At the same time, amplifications and multiplications within the RHOA putative oncogene were identified in BC and RCC. CONCLUSIONS: The data suggest that genes with potential oncogenic features are located in the close proximity to putative tumor suppressor gene(s) (TSG(s)) in the MECA3. Multiplication of the RHOA was not reported before. Significant correlation of allelic alterations in the, AP20, MECA3 and LUCA regions with tumor progression was found for some common histological tumor subtypes (e.g. clear cell RCC, and serous EOC).


Assuntos
Cromossomos Humanos Par 3/genética , Genes Supressores de Tumor , Oncogenes , Desequilíbrio Alélico/genética , Deleção Cromossômica , Progressão da Doença , Amplificação de Genes/genética , Dosagem de Genes/genética , Regulação Neoplásica da Expressão Gênica , Glutationa Peroxidase/genética , Homozigoto , Humanos , Repetições de Microssatélites/genética , Neoplasias/genética , Polimorfismo Genético , Proteína rhoA de Ligação ao GTP/genética , Glutationa Peroxidase GPX1
3.
J Pathol ; 214(1): 46-57, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17973242

RESUMO

Mutations in the von Hippel-Lindau tumour suppressor gene (VHL) cause the VHL hereditary cancer syndrome and occur in most sporadic clear cell renal cell cancers (CC-RCCs). The mechanisms by which VHL loss of function promotes tumour development in the kidney are not fully elucidated. Here, we analyse expression of PL6, one of the potential tumour suppressor genes from the critical 3p21.3 region involved in multiple common cancers. We classify PL6 as a Golgi-resident protein based on its perinuclear co-localization with GPP130 in all cells and tissues analysed. We show that PL6 RNA and protein expression is completely or partially lost in all analysed CC-RCCs and other VHL-deficient tumours studied, including the early precancerous lesions in VHL disease. The restoration of VHL function in vitro in the VHL-deficient CC-RCC cell lines was found to reinstate PL6 expression, thus establishing a direct link between VHL and PL6. Insensitivity of PL6 to hypoxia suggested that PL6 is regulated by VHL via a HIF-1-independent pathway. We ruled out mutations and promoter methylation as possible causes of PL6 down-regulation in CC-RCC. We hypothesize that loss of a putative PL6 secretory function due to VHL deficiency is an early and important event that may promote tumour initiation and growth.


Assuntos
Carcinoma de Células Renais/metabolismo , Neoplasias Renais/metabolismo , Proteínas de Membrana/metabolismo , Proteínas de Neoplasias/metabolismo , Proteína Supressora de Tumor Von Hippel-Lindau/fisiologia , Sequência de Bases , Carcinoma de Células Renais/genética , Metilação de DNA , Análise Mutacional de DNA , DNA de Neoplasias/genética , Regulação para Baixo , Células Epiteliais/metabolismo , Regulação Neoplásica da Expressão Gênica , Complexo de Golgi/metabolismo , Humanos , Subunidade alfa do Fator 1 Induzível por Hipóxia/fisiologia , Neoplasias Renais/genética , Proteínas de Membrana/genética , Dados de Sequência Molecular , Lesões Pré-Cancerosas/metabolismo , RNA Mensageiro/genética , RNA Neoplásico/genética , Distribuição Tecidual , Células Tumorais Cultivadas , Proteína Supressora de Tumor Von Hippel-Lindau/genética
4.
Oncogene ; 26(31): 4499-512, 2007 Jul 05.
Artigo em Inglês | MEDLINE | ID: mdl-17297469

RESUMO

The gene for tyrosine-kinase receptor Ron (MST1R) resides in the chromosome 3p21.3 region, frequently affected in common human malignancies. The gene generates two transcripts, 5 and 2 kb-long, full-length Ron (flRon) and short-form Ron (sfRon), respectively. Here, we show for the first time that the variegated Ron expression is associated with variations in the methylation patterns of two distinct CpG islands in Ron proximal promoter. Widespread hypermethylation associates with lack of flRon whereas hypermethylation of the distal island associates with transcription of sfRon, a constitutively active tyrosine-kinase that drives cell proliferation. sfRon inhibition with kinase-dead transgenes decreases cancer cell growth and induces cellular differentiation. sfRon could be a new drug target in cancer types in which it contributes to tumor progression.


Assuntos
Metilação de DNA , Regulação Neoplásica da Expressão Gênica , Leucemia Eritroblástica Aguda/genética , Neoplasias Pulmonares/genética , Receptores Proteína Tirosina Quinases/genética , Transcrição Gênica , Azacitidina/análogos & derivados , Azacitidina/farmacologia , Células Cultivadas , Ilhas de CpG , Decitabina , Humanos , Regiões Promotoras Genéticas , Transgenes
5.
J Pathol ; 211(5): 591-601, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17318811

RESUMO

The Fus1 gene resides in the critical 3p21.3 human chromosomal region deleted in lung and breast cancers. Recently, the tumour suppressor properties of Fus1 were confirmed experimentally by intra-tumoural administration of Fus1 that suppressed experimental lung metastasis in mice. We generated Fus1-deficient mice that were viable, fertile, and demonstrated a complex immunological phenotype. Animals with a disrupted Fus1 gene developed signs of autoimmune disease, such as vasculitis, glomerulonephritis, anaemia, circulating autoantibodies, and showed an increased frequency of spontaneous vascular tumours. Preliminary analysis of immune cell populations revealed a consistent defect in NK cell maturation in Fus1 null mice that correlated with changes in the expression of IL-15. Injection of IL-15 into Fus1 knockout mice completely rescued the NK cell maturation defect. Based on these results, we propose the hypothesis that Fus1 deficiency affects NK cell maturation through the reduction of IL-15 production but does not directly alter their developmental capacity. Since acquired immunity was not affected in Fus1-deficient animals, we suggest a relationship between the Fus1 protein and the regulation of innate immunity via IL-15 production. The increased frequency of spontaneous cancers and the development of an autoimmune syndrome in Fus1 null mice imply that these mice could serve as a model for studying molecular mechanisms of anti-tumour immunity and autoimmunity.


Assuntos
Autoimunidade/genética , Genes Supressores de Tumor/fisiologia , Interleucina-15/imunologia , Neoplasias/genética , Precursores de Proteínas/genética , Ubiquitinas/genética , Animais , Autoimunidade/imunologia , Hemangioma/genética , Hemangioma/imunologia , Hemangiossarcoma/genética , Hemangiossarcoma/imunologia , Imunidade Inata/imunologia , Células Matadoras Naturais/imunologia , Camundongos , Mitocôndrias/genética , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/imunologia , Neoplasias/imunologia , Fenótipo , Precursores de Proteínas/análise , Precursores de Proteínas/deficiência , RNA Mensageiro/genética , Distribuição Tecidual/genética , Proteínas Supressoras de Tumor , Ubiquitinas/análise , Ubiquitinas/deficiência , Vasculite/genética
6.
Oncogene ; 26(6): 802-12, 2007 Feb 08.
Artigo em Inglês | MEDLINE | ID: mdl-16878149

RESUMO

DEC1/STRA13 is a bHLH type transcriptional regulator involved with immune regulation, hypoxia response and carcinogenesis. We recently demonstrated that STRA13 interacts with STAT3 in the transcriptional activation of STAT-dependent promoters. Here, we pursue STRA13 involvement in the JAK/STAT pathway by studying its role in STAT1 expression. First, we showed that VHL deficiency or HIF-1 activation resulted in the repression of endogenous STAT1 mediated by STRA13. We then characterized the STAT1 proximal promoter to assess its response to STRA13 by transient coexpression in a luciferase reporter assay. Using sequential truncation and site-directed mutagenesis of the STAT1 promoter with STRA13 deletion constructs, we showed that the STRA13 C-terminal trans-activation domain, which is known to bind HDAC1, mostly determines the repressive activity. Involvement of HDAC activity in STAT1 regulation was validated by TSA inhibition and chromatin immunoprecipitation (ChIP) assay. Thus, we demonstrate that STRA13-mediated repression of STAT1 transcription utilizes an HDAC1-dependent mechanism. Furthermore, we show that targets of unphosphorylated STAT1, such as antigen presenting genes and CASP1, are also repressed by hypoxia possibly through the same STRA13-mediated mechanism. Thus, the newly discovered link between HIF-1 and STAT1 reveals a previously unknown role of STRA13 in hypoxia and carcinogenesis.


Assuntos
Fatores de Transcrição Hélice-Alça-Hélice Básicos/metabolismo , Regulação para Baixo , Proteínas de Homeodomínio/metabolismo , Fator 1 Induzível por Hipóxia/metabolismo , Fator de Transcrição STAT1/metabolismo , Motivos de Aminoácidos , Animais , Sequência de Bases , Hipóxia Celular/genética , Linhagem Celular , Cisteína Endopeptidases/genética , Cisteína Endopeptidases/metabolismo , Regulação Neoplásica da Expressão Gênica , Histona Desacetilases/genética , Histona Desacetilases/metabolismo , Humanos , Fator 1 Induzível por Hipóxia/deficiência , Fator 1 Induzível por Hipóxia/genética , Camundongos , Camundongos Knockout , Dados de Sequência Molecular , Regiões Promotoras Genéticas/genética , Proteínas Proto-Oncogênicas c-myb/genética , Proteínas Proto-Oncogênicas c-myb/metabolismo , Fator de Transcrição STAT1/genética , Transcrição Gênica/genética , Ativação Transcricional
8.
J Med Genet ; 42(7): 565-76, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15994878

RESUMO

BACKGROUND: STRA13 is a bHLH transcription factor that plays a crucial role in cell differentiation, proliferation, apoptosis, and response to hypoxia. OBJECTIVE: To assess STRA13 involvement in carcinogenesis and evaluate its diagnostic value. METHODS: A comprehensive analysis was undertaken of the endogenous protein expression in 389 normal and corresponding malignant specimens, using newly generated polyclonal antibodies. RESULTS: STRA13 was commonly expressed in epithelial cells of normal and neoplastic tissues where it was confined mostly to the nucleus. Intense cytoplasmic STRA13 immunoreactivity was characteristic of myoepithelial and differentiated squamous epithelial cells of all organ sites and their neoplastic counterparts, suggesting application of STRA13 as a myoepithelial cell marker. A distinctive apical granular cytoplasmic staining pattern observed in the pancreas and large intestine was retained in corresponding metastatic carcinomas, providing for identification of the primary sites of these disseminating tumours. In less differentiated tumours there was a tendency to lose the cytoplasmic staining or to switch to nuclear STRA13 staining. Analysis of STRA13, HIF-1alpha, and CAIX expression patterns in a large set of various tumours substantiated the association of STRA13 with HIF-1alpha expression and hypoxia in vivo. Investigation of the molecular mechanisms of STRA13 nucleo-cytoplasmic shuttling suggested that STRA13 employs nuclear import/export that utilises the NLS/NES motifs situated within the N-terminus and in the middle of the protein. CONCLUSIONS: STRA13 may serve as a marker for myoepithelial cells, for the degree of tumour differentiation, and for identification of the primary site of certain metastatic tumours. In combination with CAIX and CAXII markers, it may lead to a more accurate classification of all renal carcinomas.


Assuntos
Antígenos de Diferenciação/biossíntese , Fatores de Transcrição Hélice-Alça-Hélice Básicos/biossíntese , Biomarcadores Tumorais/biossíntese , Células Epiteliais/metabolismo , Proteínas de Homeodomínio/biossíntese , Neoplasias/diagnóstico , Neoplasias/metabolismo , Especificidade de Anticorpos , Antígenos de Neoplasias/biossíntese , Anidrase Carbônica IX , Anidrases Carbônicas/biossíntese , Diferenciação Celular , Linhagem Celular , Linhagem Celular Tumoral , Núcleo Celular/metabolismo , Citoplasma/metabolismo , Células Epiteliais/patologia , Humanos , Imuno-Histoquímica , Neoplasias Renais/classificação , Neoplasias Renais/diagnóstico , Neoplasias Renais/metabolismo , Neoplasias/classificação
9.
J Mol Biol ; 340(4): 641-53, 2004 Jul 16.
Artigo em Inglês | MEDLINE | ID: mdl-15223310

RESUMO

STRA13 is a pVHL-dependent bHLH transcription factor up-regulated on the mRNA level in multiple cancer cell lines and implicated recently in the regulation of immune cell homeostasis and autoimmunity. In searching for STRA13-interacting proteins with oncogenic potential by the yeast two-hybrid screening, we identified STAT3 beta as a STRA13-binding partner. We showed that STRA13 binds predominantly to phosphorylated (active) STAT3 alpha and beta isoforms via its HLH and C-terminal regions. We also found that STRA13 was able to activate transcription from STAT-dependent cis-elements. Expression of endogenous STRA13 was shown to be cytokine-inducible, consistent with STRA13 involvement in STAT-dependent transcription regulation. We demonstrated that the STAT3-regulated promoter of the pro-apoptotic Fas gene was activated upon STRA13 over-expression and that co-expression of STRA13 with STAT3 beta or STAT3 alpha modulated the transcriptional outcome. Forced expression of STRA13 induced apoptosis, in agreement with the STRA13 activation effect on the Fas promoter. Simultaneous expression of STRA13 and STAT3 beta resulted in alleviation of the STRA13 pro-apoptotic effect. Thus, for the first time, we identify STRA13 as a STAT3 partner and provide a consistent line of evidence for STRA13 involvement into regulation of apoptosis via the STAT pathways.


Assuntos
Proteínas de Ligação a DNA/metabolismo , Proteínas de Homeodomínio/metabolismo , Transativadores/metabolismo , Transcrição Gênica , Sequência de Aminoácidos , Animais , Apoptose , Fatores de Transcrição Hélice-Alça-Hélice Básicos , Western Blotting , Linhagem Celular , Proteínas de Ligação a DNA/química , Proteínas de Ligação a DNA/genética , Dimerização , Genes Reporter , Proteínas de Homeodomínio/química , Humanos , Células Jurkat , Luciferases/metabolismo , Camundongos , Células NIH 3T3 , Fosforilação , Testes de Precipitina , Isoformas de Proteínas/química , Isoformas de Proteínas/genética , Isoformas de Proteínas/metabolismo , Estrutura Terciária de Proteína , RNA Mensageiro/metabolismo , Fator de Transcrição STAT3 , Transativadores/química , Transativadores/genética , Ativação Transcricional , Técnicas do Sistema de Duplo-Híbrido , Receptor fas/metabolismo
10.
J Med Genet ; 40(4): 257-61, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12676895

RESUMO

PURPOSE: Carbonic anhydrase enzymes (CAs) are universally involved in many fundamental physiological processes, including acid base regulation and fluid formation and movement. In glaucoma patients, CA inhibitors are very effective in lowering intraocular pressure by reducing the rate of aqueous humour secretion mediated by the CAs in the ciliary epithelium. In this work, we investigated the expression and tissue distribution of two recently discovered CA genes CA9 (CAIX) and CA12 (CAXII) in fetal, neonatal, and adult human eyes with and without glaucoma. METHODS: CAIX and CAXII expression in 16 normal and 10 glaucomatous eyes, and in cultured non-pigmented ciliary epithelial cells (NPE) from normal and glaucoma eye donors was assessed by immunostaining. In addition, northern blot hybridisation was performed to assess expression of CA4, CA9, and CA12 mRNA in cultured NPE cells from normal and glaucoma donors. RESULTS: CAXII was localised primarily to the NPE with its expression prominent during embryonic eye development but which decreased significantly in adults. CAIX expression in the NPE was very low. The epithelium of cornea and lens occasionally expressed both enzymes at low levels during development and in adult eye, and no expression was detected in the retina. The NPE from glaucoma eyes expressed higher levels of CAXII, but not CAIX, in comparison with normal eyes. This expression pattern was retained in cultured NPE cell lines. NPE cells from a glaucoma patient showed a five-fold increase in the CA12 mRNA level with no detectable expression of CA9 mRNA. Also, no expression of the CA4 gene encoding a GPI anchored plasma membrane protein was detected on these northern blots. CONCLUSIONS: Transmembrane CAIX and CAXII enzymes are expressed in the ciliary cells and, thus, may be involved in aqueous humour production. CA12 may be a targeted gene in glaucoma.


Assuntos
Anidrases Carbônicas/genética , Membrana Celular/enzimologia , Glaucoma/genética , Northern Blotting , Anidrases Carbônicas/metabolismo , Células Cultivadas , Corpo Ciliar/citologia , Corpo Ciliar/enzimologia , Células Epiteliais/enzimologia , Regulação Enzimológica da Expressão Gênica , Glaucoma/enzimologia , Glaucoma/patologia , Humanos , Imuno-Histoquímica , Isoenzimas/genética , Isoenzimas/metabolismo , RNA Mensageiro/genética , RNA Mensageiro/metabolismo
11.
J Med Genet ; 39(7): 463-72, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12114475

RESUMO

The VHL gatekeeper tumour suppressor gene is inactivated in the familial cancer syndrome von Hippel-Lindau disease and in most sporadic clear cell renal cell carcinomas. Recently the VHL gene product has been identified as a specific component of a SCF-like complex, which regulates proteolytic degradation of the hypoxia inducible transcription factors HIF-1 and HIF-2. pVHL is critical for normal development and mRNA expression studies suggest a role in nephrogenesis. Despite the importance of VHL in oncogenesis and development, little is known about the regulation of VHL expression. To investigate VHL promoter activity, we performed comparative sequence analysis of human, primate, and rodent 5' VHL sequences. We then proceeded to deletion analysis of regions showing significant evolutionary conservation between human and rat promoter sequences, and defined two positive and one negative regulatory regions. Analysis of specific putative transcription factor binding sites identified a functional Sp1 site, which was shown to be a regulatory element. Overlapping Sp1/AP2 sites were also identified and candidate E2F1 binding sites evaluated. Three binding sites for as yet unidentified transcription factors were mapped also. These investigations provide a basis for elucidating the regulation of VHL expression in development, the molecular pathology of epigenetic silencing of VHL in tumourigenesis, and suggest a possible link between Sp1, VHL, and nephrogenesis.


Assuntos
Genes Supressores de Tumor/fisiologia , Ligases/genética , Regiões Promotoras Genéticas/genética , Regiões Promotoras Genéticas/fisiologia , Proteínas Supressoras de Tumor , Ubiquitina-Proteína Ligases , Doença de von Hippel-Lindau/genética , Animais , Sequência de Bases/genética , Sítios de Ligação/genética , Sítios de Ligação/fisiologia , Linhagem Celular , Sequência Conservada , DNA/genética , DNA/fisiologia , DNA de Neoplasias/genética , DNA de Neoplasias/fisiologia , Ensaio de Desvio de Mobilidade Eletroforética/métodos , Evolução Molecular , Gorilla gorilla , Células HeLa , Humanos , Rim/citologia , Rim/embriologia , Dados de Sequência Molecular , Pan troglodytes , Análise de Sequência de DNA/métodos , Deleção de Sequência/genética , Deleção de Sequência/fisiologia , Fatores de Transcrição/metabolismo , Células Tumorais Cultivadas , Proteína Supressora de Tumor Von Hippel-Lindau
12.
Cancer Res ; 61(24): 8924-9, 2001 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-11751418

RESUMO

The presence of radiation-resistant hypoxic cells in some solid tumors is known to predict for relapse after radiotherapy. Use of an endogenous marker of hypoxia would be a convenient alternative to current methods that measure tumor oxygenation, provided the marker could be shown to reliably identify viable, radiation-resistant, hypoxic cells. Carbonic anhydrase 9 (CA9) is a transmembrane protein overexpressed in a wide variety of tumor types and induced by hypoxia. Using a monoclonal antibody and cell sorting, CA9-positive cells in SiHa cervical carcinoma xenografts growing in immunodeficient mice were found to be clonogenic, resistant to killing by ionizing radiation, and preferentially able to bind the hypoxia marker pimonidazole. CA9 and pimonidazole immunostaining were compared in formalin-fixed sections from tumors of 18 patients undergoing treatment for cancer of the cervix. Excellent colocalization was observed, although the area of the tumor section that bound anti-CA9 antibodies represented double the number of cells that bound anti-pimonidazole antibodies. Occasional regions staining with pimonidazole but not CA9 could be indicative of transient changes in tumor perfusion. Results support the hypothesis that CA9 is a useful endogenous marker of tumor hypoxia.


Assuntos
Antígenos de Neoplasias , Biomarcadores Tumorais/metabolismo , Anidrases Carbônicas , Proteínas de Neoplasias/metabolismo , Oxigênio/metabolismo , Neoplasias do Colo do Útero/enzimologia , Animais , Anidrase Carbônica IX , Hipóxia Celular , Feminino , Glioma/enzimologia , Glioma/metabolismo , Humanos , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Proteínas de Neoplasias/biossíntese , Transplante de Neoplasias , Nitroimidazóis/metabolismo , Nitroimidazóis/farmacologia , Tolerância a Radiação , Radiossensibilizantes/metabolismo , Radiossensibilizantes/farmacologia , Transplante Heterólogo , Neoplasias do Colo do Útero/metabolismo , Neoplasias do Colo do Útero/radioterapia
13.
Proc Natl Acad Sci U S A ; 98(24): 13954-9, 2001 Nov 20.
Artigo em Inglês | MEDLINE | ID: mdl-11717452

RESUMO

Semaphorins SEMA3B and its homologue SEMA3F are 3p21.3 candidate tumor suppressor genes (TSGs), the expression of which is frequently lost in lung cancers. To test the TSG candidacy of SEMA3B and SEMA3F, we transfected them into lung cancer NCI-H1299 cells, which do not express either gene. Colony formation of H1299 cells was reduced 90% after transfection with wild-type SEMA3B compared with the control vector. By contrast, only 30-40% reduction in colony formation was seen after the transfection of SEMA3F or SEMA3B variants carrying lung cancer-associated single amino acid missense mutations. H1299 cells transfected with wild-type but not mutant SEMA3B underwent apoptosis. We found that lung cancers (n = 34) always express the neuropilin-1 receptor for secreted semaphorins, whereas 82% expressed the neuropilin-2 receptor. Because SEMA3B and SEMA3F are secreted proteins, we tested conditioned medium from COS-7 cells transfected with SEMA3B and SEMA3F and found that medium from wild-type SEMA3B transfectants reduced the growth of several lung cancer lines 30-90%, whereas SEMA3B mutants or SEMA3F had little effect in the same assay. Sequencing of sodium bisulfite-treated DNA showed dense methylation of CpG sites in the SEMA3B 5' region of lung cancers not expressing SEMA3B but no methylation in SEMA3B-expressing tumors. These results are consistent with SEMA3B functioning as a TSG, the expression of which is inactivated frequently in lung cancers by allele loss and promoter region methylation.


Assuntos
Apoptose , Cromossomos Humanos Par 3 , Genes Supressores de Tumor/fisiologia , Neoplasias Pulmonares/fisiopatologia , Glicoproteínas de Membrana/genética , Animais , Sequência de Bases , Células COS , Divisão Celular , Chlorocebus aethiops , Ilhas de CpG , Meios de Cultivo Condicionados , Metilação de DNA , DNA Complementar , Expressão Gênica , Humanos , Dados de Sequência Molecular , Mutagênese , Proteínas do Tecido Nervoso/biossíntese , Neuropilina-1 , Semaforinas , Transfecção , Células Tumorais Cultivadas
14.
Proc Natl Acad Sci U S A ; 98(13): 7504-9, 2001 Jun 19.
Artigo em Inglês | MEDLINE | ID: mdl-11390984

RESUMO

Clear cell-type renal cell carcinomas (clear RCC) are characterized almost universally by loss of heterozygosity on chromosome 3p, which usually involves any combination of three regions: 3p25-p26 (harboring the VHL gene), 3p12-p14.2 (containing the FHIT gene), and 3p21-p22, implying inactivation of the resident tumor-suppressor genes (TSGs). For the 3p21-p22 region, the affected TSGs remain, at present, unknown. Recently, the RAS association family 1 gene (isoform RASSF1A), located at 3p21.3, has been identified as a candidate lung and breast TSG. In this report, we demonstrate aberrant silencing by hypermethylation of RASSF1A in both VHL-caused clear RCC tumors and clear RCC without VHL inactivation. We found hypermethylation of RASSF1A's GC-rich putative promoter region in most of analyzed samples, including 39 of 43 primary tumors (91%). The promoter was methylated partially or completely in all 18 RCC cell lines analyzed. Methylation of the GC-rich putative RASSF1A promoter region and loss of transcription of the corresponding mRNA were related causally. RASSF1A expression was reactivated after treatment with 5-aza-2'-deoxycytidine. Forced expression of RASSF1A transcripts in KRC/Y, a renal carcinoma cell line containing a normal and expressed VHL gene, suppressed growth on plastic dishes and anchorage-independent colony formation in soft agar. Mutant RASSF1A had reduced growth suppression activity significantly. These data suggest that RASSF1A is the candidate renal TSG gene for the 3p21.3 region.


Assuntos
Carcinoma de Células Renais/genética , Cromossomos Humanos Par 3 , Genes Supressores de Tumor , Neoplasias Renais/genética , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Proteínas Supressoras de Tumor , Azacitidina/farmacologia , Adesão Celular , Divisão Celular/efeitos dos fármacos , Mapeamento Cromossômico , Metilação de DNA , Primers do DNA , DNA de Neoplasias/química , DNA de Neoplasias/metabolismo , Doxiciclina/toxicidade , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Regiões Promotoras Genéticas , Proteínas Recombinantes/metabolismo , Mapeamento por Restrição , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Células Tumorais Cultivadas
15.
J Natl Cancer Inst ; 93(9): 691-9, 2001 May 02.
Artigo em Inglês | MEDLINE | ID: mdl-11333291

RESUMO

BACKGROUND: The recently identified RASSF1 locus is located within a 120-kilobase region of chromosome 3p21.3 that frequently undergoes allele loss in lung and breast cancers. We explored the hypothesis that RASSF1 encodes a tumor suppressor gene for lung and breast cancers. METHODS: We assessed expression of two RASSF1 gene products, RASSF1A and RASSF1C, and the methylation status of their respective promoters in 27 non-small-cell lung cancer (NSCLC) cell lines, in 107 resected NSCLCs, in 47 small-cell lung cancer (SCLC) cell lines, in 22 breast cancer cell lines, in 39 resected breast cancers, in 104 nonmalignant lung samples, and in three breast and lung epithelial cultures. We also transfected a lung cancer cell line that lacks RASSF1A expression with vectors containing RASSF1A complementary DNA to determine whether exogenous expression of RASSF1A would affect in vitro growth and in vivo tumorigenicity of this cell line. All statistical tests were two-sided. RESULTS: RASSF1A messenger RNA was expressed in nonmalignant epithelial cultures but not in 100% of the SCLC, in 65% of the NSCLC, or in 60% of the breast cancer lines. By contrast, RASSF1C was expressed in all nonmalignant cell cultures and in nearly all cancer cell lines. RASSF1A promoter hypermethylation was detected in 100% of SCLC, in 63% of NSCLC, in 64% of breast cancer lines, in 30% of primary NSCLCs, and in 49% of primary breast tumors but in none of the nonmalignant lung tissues. RASSF1A promoter hypermethylation in resected NSCLCs was associated with impaired patient survival (P =.046). Exogenous expression of RASSF1A in a cell line lacking expression decreased in vitro colony formation and in vivo tumorigenicity. CONCLUSION: RASSF1A is a potential tumor suppressor gene that undergoes epigenetic inactivation in lung and breast cancers through hypermethylation of its promoter region.


Assuntos
Neoplasias da Mama/genética , Carcinoma Pulmonar de Células não Pequenas/genética , Carcinoma de Células Pequenas/genética , Metilação de DNA , Genes Supressores de Tumor , Neoplasias Pulmonares/genética , Proteínas de Neoplasias/genética , Regiões Promotoras Genéticas , Proteínas Supressoras de Tumor , Adulto , Idoso , Ilhas de CpG , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fenótipo , Reação em Cadeia da Polimerase , Células Tumorais Cultivadas
16.
Oncogene ; 20(12): 1509-18, 2001 Mar 22.
Artigo em Inglês | MEDLINE | ID: mdl-11313894

RESUMO

Previously we analysed overlapping homozygous deletions in lung and breast tumours/tumour lines and defined a small region of 120 kb (part of LCTSGR1) at 3p21.3 that contained putative lung and breast cancer tumour suppressor gene(s) (TSG). Eight genes including RASSF1 were isolated from the minimal region. However, extensive mutation analysis in lung tumours and tumour lines revealed only rare inactivating mutations. Recently, de novo methylation at a CpG island associated with isoform A of RASSF1 (RASSF1A) was reported in lung tumours and tumour lines. To investigate RASSF1A as a candidate TSG for various cancers, we investigated: (a) RASSF1A methylation status in a large series of primary tumour and tumour lines; (b) chromosome 3p allele loss in lung tumours and (c) RASSF1 mutation analysis in breast tumours. RASSF1A promoter region CpG island methylation was detected in 72% of SCLC, 34% of NSCLC, 9% of breast, 10% of ovarian and 0% of primary cervical tumours and in 72% SCLC, 36% NSCLC, 80% of breast and 40% of ovarian tumour lines. In view of the lower frequency of RASSF1 methylation in primary breast cancers we proceeded to RASSF1 mutation analysis in 40 breast cancers. No mutations were detected, but six single nucleotide polymorphisms were identified. Twenty of 26 SCLC tumours with 3p21.3 allelic loss had RASSF1A methylation, while only six out of 22 NSCLC with 3p21.3 allele loss had RASSF1A methylation (P=0.0012), one out of five ovarian and none out of six cervical tumours with 3p21.3 loss had RASSF1A methylation. These results suggest that (a) RASSF1A inactivation by two hits (methylation and loss) is a critical step in SCLC tumourigenesis and (b) RASSF1A inactivation is of lesser importance in NSCLC, breast, ovarian and cervical cancers in which other genes within LCTSGR1 are likely to be implicated.


Assuntos
Transformação Celular Neoplásica , Cromossomos Humanos Par 3 , Metilação de DNA , Inativação Gênica , Genes Supressores de Tumor/genética , Proteínas de Neoplasias/genética , Proteínas Supressoras de Tumor , Sequência de Aminoácidos , Sequência de Bases , Neoplasias da Mama/genética , Carcinoma Pulmonar de Células não Pequenas/genética , Carcinoma de Células Pequenas/genética , Ilhas de CpG , Feminino , Humanos , Perda de Heterozigosidade , Neoplasias Pulmonares/genética , Dados de Sequência Molecular , Estadiamento de Neoplasias , Neoplasias Ovarianas/genética , Polimorfismo de Nucleotídeo Único , Regiões Promotoras Genéticas , Células Tumorais Cultivadas , Neoplasias do Colo do Útero/genética
18.
Proc Natl Acad Sci U S A ; 98(8): 4443-8, 2001 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-11296287

RESUMO

Jaagsiekte sheep retrovirus (JSRV) can induce rapid, multifocal lung cancer, but JSRV is a simple retrovirus having no known oncogenes. Here we show that the envelope (env) gene of JSRV has the unusual property that it can induce transformation in rat fibroblasts, and thus is likely to be responsible for oncogenesis in animals. Retrovirus entry into cells is mediated by Env interaction with particular cell-surface receptors, and we have used phenotypic screening of radiation hybrid cell lines to identify the candidate lung cancer tumor suppressor HYAL2/LUCA2 as the receptor for JSRV. HYAL2 was previously described as a lysosomal hyaluronidase, but we show that HYAL2 is actually a glycosylphosphatidylinositol (GPI)-anchored cell-surface protein. Furthermore, we could not detect hyaluronidase activity associated with or secreted by cells expressing HYAL2, whereas we could easily detect such activity from cells expressing the related serum hyaluronidase HYAL1. Although the function of HYAL2 is currently unknown, other GPI-anchored proteins are involved in signal transduction, and some mediate mitogenic responses, suggesting a potential role of HYAL2 in JSRV Env-mediated oncogenesis. Lung cancer induced by JSRV closely resembles human bronchiolo-alveolar carcinoma, a disease that is increasing in frequency and now accounts for approximately 25% of all lung cancer. The finding that JSRV env is oncogenic and the identification of HYAL2 as the JSRV receptor provide tools for further investigation of the mechanism of JSRV oncogenesis and its relationship to human bronchiolo-alveolar carcinoma.


Assuntos
Transformação Celular Neoplásica , Transformação Celular Viral/fisiologia , Genes Supressores de Tumor , Glicosilfosfatidilinositóis/fisiologia , Hialuronoglucosaminidase/metabolismo , Retrovirus Jaagsiekte de Ovinos/fisiologia , Fusão de Membrana , Carcinoma de Células Pequenas/patologia , Genes env , Humanos , Hialuronoglucosaminidase/genética , Retrovirus Jaagsiekte de Ovinos/genética , Neoplasias Pulmonares/patologia , Fosfatidilinositol Diacilglicerol-Liase , Células Tumorais Cultivadas , Fosfolipases Tipo C/metabolismo
19.
J Biol Chem ; 276(18): 15306-15, 2001 May 04.
Artigo em Inglês | MEDLINE | ID: mdl-11278694

RESUMO

In this study, we focus on different modes of regulation of STRA13, a human ortholog of the mouse basic helix-loop-helix transcriptional factor, previously identified by us as a new von Hippel-Lindau tumor suppressor gene (VHL) target. The gene was overexpressed in VHL-deficient cell lines and tumors, specifically clear cell renal carcinomas and hemangioblastomas. Introduction of wild type VHL transgene into clear cell renal carcinoma restored low level expression of STRA13. Overexpression was also detected in many common malignancies with an intact VHL gene, suggesting the existence of another, VHL-independent pathway of STRA13 regulation. Similar to many other von Hippel-Lindau tumor-suppressor protein (pVHL) targets, the expression of STRA13 on the mRNA level was hypoxia-sensitive, indicating oxygen-dependent regulation of the gene, presumably through the pVHL/hypoxia-inducible factor 1 (HIF-1) pathway. The yeast two-hybrid screening revealed interaction of the STRA13 protein with the human ubiquitin-conjugating enzyme (UBC9) protein, the specificity of which was confirmed in mammalian cells. By adding the proteasome inhibitor acetyl-leucinyl-leucinyl-norleucinal, we demonstrated that the 26 S proteasome pathway regulates the stability of pSTRA13. Co-expression of STRA13 and UBC9 led to an increase of the pSTRA13 ubiquitination and subsequent degradation. These data established that UBC9/STRA13 association in cells is of physiological importance, presenting direct proof of UBC9 involvement in the ubiquitin-dependent degradation of pSTRA13. Hypoxia treatment of mammalian cells transiently expressing STRA13 protein showed that stability of pSTRA13 is not affected by hypoxia or VHL. Thus, STRA13, a new pVHL target, is regulated in cells on multiple levels. We propose that STRA13 may play a critical role in carcinogenesis, since it is a potent transcriptional regulator, abundant in a variety of common tumors.


Assuntos
Hipóxia Celular , Cisteína Endopeptidases/metabolismo , Regulação da Expressão Gênica/fisiologia , Genes Supressores de Tumor , Proteínas de Homeodomínio/genética , Neoplasias Renais/genética , Ligases/fisiologia , Complexos Multienzimáticos/metabolismo , Proteínas/fisiologia , Proteínas Supressoras de Tumor , Enzimas de Conjugação de Ubiquitina , Ubiquitina-Proteína Ligases , Fatores de Transcrição Hélice-Alça-Hélice Básicos , Linhagem Celular , Proteínas de Homeodomínio/química , Proteínas de Homeodomínio/metabolismo , Humanos , Hidrólise , Neoplasias Renais/patologia , Ligases/metabolismo , Complexo de Endopeptidases do Proteassoma , Ligação Proteica , Proteínas/genética , Frações Subcelulares/metabolismo , Células Tumorais Cultivadas , Proteína Supressora de Tumor Von Hippel-Lindau
20.
Am J Pathol ; 158(3): 905-19, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11238039

RESUMO

An acidic extracellular pH is a fundamental property of the malignant phenotype. In von Hippel-Lindau (VHL)-defective tumors the cell surface transmembrane carbonic anhydrase (CA) CA9 and CA12 genes are overexpressed because of the absence of pVHL. We hypothesized that these enzymes might be involved in maintaining the extracellular acidic pH in tumors, thereby providing a conducive environment for tumor growth and spread. Using Northern blot analysis and immunostaining with specific antibodies we analyzed the expression of CA9 and CA12 genes and their products in a large sample of cancer cell lines, fresh and archival tumor specimens, and normal human tissues. Expression was also analyzed in cultured cells under hypoxic conditions. Expression of CA IX and CA XII in normal adult tissues was detected only in highly specialized cells and for most tissues their expression did not overlap. Analysis of RNA samples isolated from 87 cancer cell lines and 18 tumors revealed high-to-moderate levels of expression of CA9 and CA12 in multiple cancers. Immunohistochemistry revealed high-to-moderate expression of these enzymes in various normal tissues and multiple common epithelial tumor types. The immunostaining was seen predominantly on the cell surface membrane. The expression of both genes was markedly induced under hypoxic conditions in tumors and cultured tumor cells. We conclude that the cell surface trans-membrane carbonic anhydrases CA IX and CA XII are overexpressed in many tumors suggesting that this is a common feature of cancer cells that may be required for tumor progression. These enzymes may contribute to the tumor microenvironment by maintaining extracellular acidic pH and helping cancer cells grow and metastasize. Our studies show an important causal link between hypoxia, extracellular acidification, and induction or enhanced expression of these enzymes in human tumors.


Assuntos
Anidrases Carbônicas/biossíntese , Hipóxia Celular , Concentração de Íons de Hidrogênio , Neoplasias/enzimologia , Neoplasias/etiologia , Biomarcadores Tumorais/biossíntese , Northern Blotting , Anidrases Carbônicas/genética , Anidrases Carbônicas/imunologia , Carcinoma de Células Renais/diagnóstico , Carcinoma de Células Renais/enzimologia , Técnicas de Cultura de Células/métodos , Diferenciação Celular , Divisão Celular , Perfilação da Expressão Gênica , Regulação Neoplásica da Expressão Gênica , Glioblastoma/enzimologia , Humanos , Imuno-Histoquímica , Neoplasias Renais/diagnóstico , Neoplasias Renais/enzimologia , Proteínas de Membrana/biossíntese , Proteínas de Membrana/genética , Proteínas de Membrana/imunologia , Modelos Biológicos , Neoplasias/genética , Isoformas de Proteínas/biossíntese , Isoformas de Proteínas/genética , Isoformas de Proteínas/imunologia , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...